• Aarti Drugs reported 11% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended December (Q3FY22). On a year-on-year (YoY) basis, it witnessed a growth of 21%.
  • Its expenses for the quarter were up 7% QoQ and 27% YoY.
  • While the company reported a net profit of 37% QoQ, the same fell by 14% on a YoY basis.
  • The earnings per share (EPS) of Aarti Drugs stood at 6.3 during Q3FY22.

Tata Motors Financial Statements for Q3FY22:

(Rs, crores) Q3FY21 Q2FY22 Q3FY22 QoQ (%) YoY (%)
Total Income 532 580 641 11% 21%
Total Expenses 442 524 563 7% 27%
Profit before tax 90 56 79 40% -13%
Tax 22 14 20 51% -9%
Profit after tax 68 43 58 37% -14%
Earnings per share 7.3 4.6 6.3    

Data Source: BSE, Company announcements

Want to get more analysis on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results